In this paper by Fei Ma and colleagues (BMJ 2023;383:e076065; doi:10.1136/bmj-2023-076065), published on 31 October 2023, an error to the affiliation of author Tao Sun was introduced during the editing process. Professor Tun’s affiliation is Breast Internal Medicine Department, Liaoning Cancer Hospital & Institute, Shenyang, China. This has been corrected.
. 2023 Nov 16;383:p2665. doi: 10.1136/bmj.p2665
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
Collection date 2023.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
PMCID: PMC10652813 PMID: 37973164
